Propranolol clinical trials
Propranolol is named as an intervention in 25 current clinical trials in our China, France, South Korea, Canada, Egypt, Germany, Turkey, Brazil, Denmark, USA, Spain, Taiwan, Switzerland, Sweden, Norway and Mexico registers. 15 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Second Xiangya Hospital of Central South University (3). The most-studied condition is Cirrhosis. The EU clinical trials register (CTIS) separately lists 4 authorised or ongoing trials.
Where Propranolol is approved
All regulators →Of the three regulators tracked here, the first to approve Propranolol was the US, on 13 Nov 1967. It is approved in 3 of the 3 regulators tracked here.
- 4 EU orphan designations, most recently for treatment of familial cerebral cavernous malformations (11 Nov 2022, positive)
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
Propranolol patents and exclusivity
Expiry tracker →Protections still running for marketed products containing Propranolol, as listed by the regulators. Expired patents and exclusivities, and discontinued products, are not shown.
- 2 listed patents; the last listed expires 16 Oct 2028 (US 8338489).
Reproduced from the FDA Orange Book and Purple Book (checked 8 Nov 2026) and the European Commission's Union Register of medicinal products (CC BY 4.0; the EU expiry date is calculated exactly as the Commission's register displays it). Listed patents and dates are as submitted to or published by the regulator and may not reflect litigation, invalidation, settlements, lapsed fees or later extensions. This is not legal advice or a freedom-to-operate opinion, and it does not say when a generic or biosimilar will launch.
What health systems spend on Propranolol
All medicines →From NHSBSA Prescription Cost Analysis (Open Government Licence v3.0) and CMS State Drug Utilization Data. Both are gross amounts: neither system publishes its discounts or rebates per drug. Products combining several substances are not counted here.
How Propranolol works
All drug targets →- Beta-1 adrenergic receptor antagonist AntagonistTarget: ADRB1 adrenoceptor beta 1ChEMBL only
- Beta-2 adrenergic receptor antagonist AntagonistTarget: ADRB2 adrenoceptor beta 2✓ In ChEMBL and the Guide to Pharmacology
- Partial agonist at ADRB3 Primary targetTarget: ADRB3 adrenoceptor beta 3Guide to Pharmacology only
- AscitesPhase 3
- Portal vein thrombosisPhase 3
- Supraventricular tachycardiaPhase 3
- TachycardiaPhase 3
- Brain edemaPhase 3
- Capillary hemangiomaPhase 3
- CardiotoxicityPhase 3
- Cirrhosis of liverPhase 3
- Colon carcinomaPhase 3
- Congestive heart failurePhase 3
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL27, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 564, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Propranolol
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- IEIreland: 7 products on the HPRA listEach product record links to the HPRA, which publishes the leaflet and SmPC.
- EUEuropean Union: HemangiolEMA product information: package leaflet and summary of product characteristics in every EU language.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Reference identifiers for Propranolol
- ATC code
- C07AA05
- ChEMBL
- CHEMBL27
- DrugBank
- DB00571
- PubChem CID
- 4946
- CAS number
- 525-66-6
- FDA UNII
- 9Y8NXQ24VQ
- Wikidata
- Q423364
- Wikipedia
- Propranolol
Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.
Trials by status
Trials by phase
Clinical trials of Propranolol
25 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Propranolol in the EU trials register (CTIS)
4 trialsAuthorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Propranolol. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
Propranolol across our data
Ireland · EU · USThe same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
Licensed in Ireland (HPRA)
7 single-substance products containing Propranolol on the HPRA medicines list.
- Beta-Prograne 160mg Prolonged-Release CapsulesTillomed Pharma GmbH · PA22720/002/001 · Marketed
- Half Beta-Prograne 80 mg Prolonged-Release CapsulesTillomed Pharma GmbH · PA22720/002/002 · Marketed
- Propranolol Azure 10 mg film-coated tabletsAzure Pharmaceuticals Ltd. · PA22871/031/001 · Marketed
- Propranolol Azure 40 mg film-coated tabletsAzure Pharmaceuticals Ltd. · PA22871/031/002 · Marketed
- HEMANGIOL 3.75 mg/mL oral solutionPierre Fabre Dermatologie · EU/1/14/919/001
Supply shortages
- Propranolol Hydrochloride InjectionUS (FDA) · Current · updated 3 Nov 2026
- Propranolol AL 80Germany (BfArM) · Other reason · 25 Feb 2026 to 27 Nov 2026
Recent approvals
- Propranolol HydrochlorideFDA · 26 Oct 2026 · Generic (ANDA) · Senores Pharms
Conditions studied with Propranolol
38 conditionsAll 38 conditions
| Condition (as registered) | Trials |
|---|---|
| Cirrhosis | 2 |
| Propranolol | 2 |
| Pancreatic Cancer | 2 |
| Carcinoma, Non-Small-Cell Lung | 1 |
| Bladder Urothelial Carcinoma | 1 |
| Lymph Node Metastasis | 1 |
| Gastrointestinal Tumors | 1 |
| Infantile Hemangioma | 1 |
| Rebleeding of Portal Hypertension in Liver Cirrhosis | 1 |
| Carvedilol | 1 |
| Prostate Cancer | 1 |
| Retinopathy of Prematurity | 1 |
| Post-Traumatic Stress Disorder, PTSD | 1 |
| PTSD | 1 |
| Soft Tissue Sarcoma Adult | 1 |
| Angiosarcoma | 1 |
| Undifferentiated Pleomorphic Sarcoma | 1 |
| Surgery | 1 |
| Hepatocellular Cancer | 1 |
| Biliary Tract Cancer | 1 |
| Cholangiocarcinoma | 1 |
| Kaposi Sarcoma | 1 |
| Breast Cancer | 1 |
| Myocardial Injury After Noncardiac Surgery (MINS) | 1 |
| Decompensated Cirrhosis of Liver | 1 |
| TBI Traumatic Brain Injury | 1 |
| Traumatic Brain Injury (TBI) Patients | 1 |
| Intracranial Pressure | 1 |
| Intensive Care Unit | 1 |
| Mortality | 1 |
| Non Small Cell Lung Cancer | 1 |
| Resectable Non-Small-Cell Lung Cancer | 1 |
| Small Cell Lung Cancer (SCLC) | 1 |
| Ovarian Cancer | 1 |
| Vasoconstriction | 1 |
| Vasodilation | 1 |
| Postural Tachycardia Syndrome | 1 |
| Beta Blocker Toxicity | 1 |
Sponsors
lead sponsor per trial+ 7 more sponsors in the trial list above.
By country register
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
Related compounds
Questions about Propranolol trials
How many clinical trials are testing Propranolol?
25 current trials in our China, France, South Korea, Canada, Egypt, Germany, Turkey, Brazil, Denmark, USA, Spain, Taiwan, Switzerland, Sweden, Norway and Mexico registers name Propranolol (also registered as Propranolol 4-week course) as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.
Are Propranolol trials recruiting patients?
Yes. 15 of the 25 trials are recruiting: 6 with sites in China, 1 with sites in France, 2 with sites in Canada, 2 with sites in Egypt, 1 with sites in Germany, 1 with sites in Turkey, 1 with sites in Brazil, 2 with sites in Denmark, 1 with sites in Switzerland, 1 with sites in Sweden, 1 with sites in Norway and 1 with sites in Mexico. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Propranolol clinical trials?
Second Xiangya Hospital of Central South University (3), University Hospital, Toulouse (2), Janssen Research & Development, LLC (1) and Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (1), among 22 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Is Propranolol licensed in Ireland?
Yes. The HPRA medicines list includes 7 single-substance products containing Propranolol, for example Beta-Prograne 160mg Prolonged-Release Capsules (Tillomed Pharma GmbH). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
Is there a Propranolol shortage?
The registers we track list 2 entries for Propranolol: US FDA: current; 1 German notice. Shortages are product- and country-specific; check with a pharmacist.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Propranolol works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Propranolol works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Propranolol (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.